Skip to content
Toviaz(fesoterodine)
Toviaz (fesoterodine) is a small molecule pharmaceutical. Fesoterodine was first approved as Toviaz on 2007-04-20. It is used to treat urge urinary incontinence in the USA. It has been approved in Europe to treat overactive urinary bladder.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
urogenital diseasesD000091642
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Toviaz (generic drugs available since 2015-12-10)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fesoterodine fumarate
Tradename
Company
Number
Date
Products
TOVIAZMylanN-022030 RX2008-10-31
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
fesoterodine fumarateANDA2023-01-30
toviazNew Drug Application2022-11-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
urge urinary incontinenceEFO_0006865D053202N39.41
Agency Specific
FDA
EMA
Expiration
Code
FESOTERODINE FUMARATE, TOVIAZ, PFIZER
2024-12-17PED
2024-06-17I-861
Patent Expiration
Patent
Expires
Flag
FDA Information
Fesoterodine Fumarate, Toviaz, Pfizer
78077152027-06-07DPU-913
80883982027-06-07DPU-913
85017232027-06-07DP
ATC Codes
G: Genito urinary system and sex hormones
— G04: Urologicals
— G04B: Urologicals
— G04BD: Drugs for urinary frequency and incontinence
— G04BD11: Fesoterodine
HCPCS
No data
Clinical
Clinical Trials
59 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Overactive urinary bladderD053201EFO_1000781N32.81738131041
Urinary incontinenceD014549HP_0000020R321——113
Urge urinary incontinenceD053202EFO_0006865N39.41——11—2
Parkinson diseaseD010300EFO_0002508G20———1—1
AdenocarcinomaD000230———1—1
Urinary bladder neck obstructionD001748EFO_1000840N32.0———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neurogenic urinary bladderD001750HP_0000011N31——2——2
NocturiaD053158R35.1—11——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Autonomic dysreflexiaD020211EFO_1001762G90.4—1———1
Cognitive dysfunctionD060825G31.84—1———1
Stress urinary incontinenceD014550HP_0010992—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—4————4
Therapeutic equivalencyD0138101————1
FoodD005502STY/T1681————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameFESOTERODINE
INNfesoterodine
Description
Fesoterodine is a diarylmethane.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)C(=O)Oc1ccc(CO)cc1[C@H](CCN(C(C)C)C(C)C)c1ccccc1
Identifiers
PDB—
CAS-ID286930-02-7
RxCUI797195
ChEMBL IDCHEMBL1201764
ChEBI ID—
PubChem CID6918558
DrugBankDB06702
UNII ID621G617227 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Toviaz - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 594 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15 adverse events reported
View more details